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Abstract 
Background: To analyze the spectrum of 
neuroblastoma and burden of high risk malignancy 
on the public sector tertiary center.  
Methods: In this descriptive study, 70 patients 
with neuroblastoma were enrolled. Data regarding 
their age, sex, type (infantile <547 days or 18 months 
or more than 18 months), staging and clinical 
features, bone and bone marrow involvement, course 
of therapy and outcome was analyzed .  The staging 
was done on the basis of bilateral bone marrow 
biopsy and imaging CT Scans, MRI neck chest and 
abdomen and bone scans. Patients were treated with 
conventional  vincristine, cyclophosphamide, 
doxorubicin, etoposide and carboplatin for 6-8 
courses 2-3 weeks apart depending upon the age 
whether 18 months or older group. Evaluation was 
done after 2-4 courses to see the response and 
options for surgery by doing imaging in the form of 
MRI or CT scans.  
Results: Total 70 patients with age ranging from< 1 
year to 15 years (median age of 3 yrs) were included. 
M: F Ratio was 1.8:1. Non-infantile type (70%), stage 
IV (79%) and adrenal mass (47%) were the 
commonest presentations. Bone and bone marrow 
involvement was seen in 53% and 70% , respectively. 
Thirty out of seventy (43%) successfully completed 
the chemotherapy, 12/70(17%) abandoned treatment, 
17/70 (24%) expired due to progressive disease and 
infections, 7/70(10%) were put on palliative 
treatment at presentation 4/70(6%) relapsed and 
given palliation therapy.  
Conclusion: In resource limited settings, 
neuroblastoma stage IV is a challenging malignancy 
to deal with. There is intense need of increased 
capacity building to diagnose them early and 
implementation of effective infection control 
measures with better survival options in these 
patients. 
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Introduction 
Neuroblastoma is the most common extracranial solid 
tumor in childhood in high income countries , where it 
accounts for 10% of pediatric cancers. 1 In low- and 
middle- income countries (LMIC) with population-
based registries, it accounts for only 1–3% of cancers, 
and in most LMIC its true incidence is unknown. 2-4   
Neuroblastoma is the most common extracranial solid 
tumour in childhood, accounting for 50% of neoplasms 
diagnosed in the first year of life. 5 Neuroblastoma is 
the most common neonatal solid tumour (47%) 
followed by germ cell tumours 28.8% in France in a 
study done from 2000-2009 with overall survival of 
84% and most common site is abdomen 86% followed 
by chest and neck. 6 Neuroblastoma, the second most 
common childhood solid tumour, accounts for 8% of 
all childhood (0–14 years) cancers in the United 
Kingdom. However, survival remains poor for 
children diagnosed with high-risk disease (50% of all 
neuroblastoma).7  
This disease has a heterogeneous course, ranging from 
spontaneous regression to inexorable progression and 
death, depending on the biologic features of the 
tumor. Identification of risk groups on the basis of 
clinical and molecular prognostic variables has 
allowed tailoring of therapy to improve outcomes and 
minimize the risk of deleterious consequences of 
therapy.8 Neuroblastoma is notable for its broad range 
of clinical behaviors. Tailored treatment approaches, 
based on the presence or absence of specific clinical 
and biologic factors, have been used for decades, and 
successive institutional and cooperative group risk 
based clinical trials have led to substantial 
improvement in outcome for patients classified as low 
or intermediate risk. 9 Outcomes for the vast majority 
of patients with low-stage (International 
Neuroblastoma Staging System [INSS] stages 1 and 2) 
neuroblastoma are excellent. Local recurrences can 
typically be managed with surgery and/or radiation 
therapy. Metastatic recurrences are rare and often 
treated successfully with chemotherapy. Treatment of  
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patients with localized neuroblastoma with 
unfavourable biologic features is controversial. Among 
patients with low-stage, MYCN-amplified 
neuroblastoma, outcomes of patients with 
hyperdiploid tumors were statistically, significantly 
better than those with diploid tumors.10 Advanced 
neuroblastoma is a systemic disease that spreads to the 
whole body, including the bone marrow, liver, lymph 
nodes, and bones. Morphologic or radiologic methods 
only detect metastases larger than a certain size. This 
indicates that high-risk neuroblastoma should be 
considered as a systemic disease and that an increase 
of chemotherapy intensity is a premise for the 
improvement of treatment outcome. High dose 
chemotherapy (HDC), with stem cell salvage following 
intensive induction chemotherapy has been widely 
accepted as being required for neuroblastoma 
treatment in high-risk groups, and treatment results 
have improved. However, the 5-year event-free 
survival (EFS) rate is 30–40% and remains 
unsatisfactory despite various intensive efforts. 9, 11In 
low income countries like Pakistan advanced 
neuroblastoma, with dismal outcome, at presentation 
is more common. 
  
Patients and Methods 
 In this descriptive study, performed in the 
department of Paediatric Haematology/ Oncology of 
the Children’s Hospital Lahore from June 2015 to 
December 2016, patients with neuroblastoma were 
enrolled. Data regarding their age, sex, type (infantile 
<547 days or 18 months or more than 18 months), 
staging and clinical features, bone and bone marrow 
involvement, course of therapy and outcome was 
analyzed. Criteria of entry were children with 
diagnosis of neuroblastoma based on physical 
examination, basic laboratory, radiographic and 
pathologic evaluation along with 
immunohistochemistry (IHC) in all cases. The staging 
was done on the basis of bilateral bone marrow biopsy 
and imaging CT Scans, MRI neck chest and abdomen 
and bone scans. Patients were treated with 
conventional  vincristine, cyclophosphamide, 
doxorubicin, etoposide and carboplatin for 6-8 courses 
2-3 weeks apart depending upon the age whether 18 
months or older group. Evaluation was done after 2-4 
courses to see the response and options for surgery by 
doing imaging in the form of MRI or CT scans. No 
facility was available in our center for myeloablative 
chemotherapy with autologous hematopoietic stem 
cell rescue and immunotherapy for minimal residual 
disease to decrease relapse in high risk disease. 
Results 
Total 70 patients with age ranging from< 1 year to 15 
years (median age of 3 yrs) were included. Five 
patients were more than 10 years (7%). M: F Ratio was 
1.8:1. Forty nine cases were of non-infantile type(>18 
months old) and 21 (30%) with infantile type 
(>18months).Fifteen (22%) had stage III at presentation 
while 55 (78%) was of stage IV. No one presented at 
stage I or II.  Thirty three (47%) had mainly adrenal 
mass as the main presenting complaint, 5 (7%) as 
paraplegia, 4 (6%) as nasal polyp, neck and 
mediastinal involvement , 2  (3%) as bony masses and 
proptosis, 26  (37%)with  multiple presentations. Fifty 
two (74%) had to travel more than 100 km to reach the 
primary treatment center. Thirty seven (53%) had bone 
involvement at presentation and 49(70%) had bone 
marrow involvement. Thirty (43%) had successfully 
completed the chemotherapy followed by surgical 
resection and radiotherapy if required for residual 
tumour, 12 (17%) abandoned treatment, 17 (24%) 
expired due to progressive disease and infections, 
7(10%) were put on palliative therapy at presentation 4 
(6%) were put on palliation after relapse (Table 1 &2). 
Table 1: Staging and Outcome 
Stage treatment 
Complete 
treatment 
Abandoned 
Expired Palliation 
on 
arrival 
Palliation 
after 
Relapse 
 
III 7 0 6 0 2 15 
IV 23 12 11 7 2 55 
Total  30 12 17 7 4 70 
p-value-0.05 
 
Table 2: Staging and clinical spectrum 
Stage Adrenal 
mass 
Multiple 
presentat
ions 
Non-
Adrenal 
masses 
Total  
 
 
p-
value=0
.019 
Stage 
III 
9 1 5 15 
Stage 
IV 
24 25 6 55 
total 33 26 11 70 
% 47% 37% 16%  
 
              
 
 
 
 
Figure 1: Round Blue 
Cell Tumour 
Figure 2: Advanced stage 
Neuroblastoma at presentation 
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Discussion 
This is the most common extra-cranial solid tumour in 
West, however it is 4th most common solid tumour 
after lymphomas and Wilms tumor in our center. 
Neuroblastoma is uncommon in Africa with Burkitt’s 
lymphoma being the commonest, but when seen 
usually presents as high-risk disease with a poor 
prognosis with overall survival of 4%. This aggressive 
biology of the tumor is frequently augmented by 
delayed presentation. Current treatment depends 
upon technologies and skills that are scarce in 
developing countries and the cost involved is 
generally beyond the means of healthcare providers 
who are faced with a myriad more pressing healthcare 
issues. 12 It is more common in males almost twice than 
females in our study as compared to SEER pediatric 
monograph illustrated that the overall incidence 
among males was 6.5% higher compared with that of 
females.13 Seventy percent presented at older age 
group > 18 months in our study as compared to data 
analyzed in over 8800 children with neuroblastoma 
from 1999-2002 and 17% having stage III, 43% 
presented at >18 months age with age < 18 months 
having prognostic value with better 5-year overall 
survival of 95% than 76% in older age group having 
INSS stage III cohort (p-value=<0.001).14  NB incidence 
peaks in infancy and then rapidly declines, with less 
than 5% of cases diagnosed in children and 
adolescents >10 years. There is increasing evidence 
that neuroblastoma in older children and adolescents 
has unique biology and an indolent disease course, but 
ultimately dismal survival. 15 
In present  study  there was no patient with localized 
disease and stage IV in more than two third of cases as 
compared to another study done in Morocco they had 
more than a third of cases of localized neuroblastoma 
(INSS Stage I II) In 61.1% of cases, tumors were 
widespread at the diagnosis, whereas 38.9% did not 
extend beyond the primary site. Similar is the case in 
HIC for the proportion of low- stage neuroblastoma as 
shown by data from INRG International 
Neuroblastoma Risk Group (30%) had low-stage 
(International Neuroblastoma Staging System INSS 
stages 1 and 2) neuroblastoma (2660/8800 cases) from 
1990 to 2002.10, 16 
Present study showed that two thirds of these 
neuroblastoma patients had bone marrow 
involvement and more than half had bony metastases 
at their first presentation indicating their advanced 
stages due to late diagnoses . High risk Neuroblastoma 
requires modern high-risk treatment regimens include 
five to six cycles of induction chemotherapy and 
surgery, consolidation therapy with high-dose therapy 
(HDT) with autologous hematopoietic stem-cell rescue 
and irradiation, and post consolidation therapy to treat 
minimal residual disease. As these regimens are not 
available in our center therefore these patients are 
inadequately treated or put on palliation as 
demonstrated by SIOP-PODC working group in their 
study. Due to the lack of transplant expertise, reduced 
access to blood products and pharesis, and difficulty 
supporting patients through the period of 
myelosuppression, few  centers in LMIC have 
attempted curative treatment of high-risk 
neuroblastoma, and have commonly prescribed 
palliative care. Furthermore, the cost of isotretinoin 
and lack of access to monoclonal anti-GD2 antibody 
impede effective MRD treatment in some LMIC. 17 
Neuroblastoma is one of the most difficult childhood 
cancers to cure with UK and Ireland 5-year survival of 
64.7% for cases diagnosed. The greatest improvements 
were in Eastern Europe, where 5-year survival 
increased  from 65.2% in 1999-2001, to 70.2% in 2005-
07. 18 In low income countries Only a limited 
proportion of all children with cancer receive curative 
and/or palliative  therapy. 19, 20 
 Majority of these children in our study presented with 
adrenal masses along with other presentations and less 
than 5% had mediastinal disease as a main clinical 
spectrum and 7% had spinal masses presenting as 
paraplegia. As compared to another study done on 
children younger than age 21 years diagnosed with NB 
or ganglioneuroblastoma between 1990 and 2002 and 
with known primary site were identified from the 
International Neuroblastoma Risk Group INRG 
database. Patients with adrenal tumours had higher 
risk of events and more frequent poor prognostic 
clinical and biological factors (Stage IV disease, MYCN 
amplification, elevated serum ferritin and LDH and 
chromosomal aberrations) than in non-adrenal 
tumours (p-value=0.001). 21  
Figure 3: Infantile 
neuroblastoma 
 
Figure 4: Bony Metastases 
and right proptosis at 
presentation. 
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Conclusion 
In resource limited settings, neuroblastoma stage IV is 
a challenging malignancy to deal with. There is intense 
need of increased capacity building to diagnose them 
early and treat in earliest possible staging for better 
results. 
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